Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 17, 2017 17:15 ET | Source: ZIOPHARM Oncology, Inc.

ZIOPHARM Oncology Announces Results of Ad-RTS-hIL-12 + Veledimex in Recurrent Glioblastoma to be Presented at the 2017 ASCO Annual Meeting

BOSTON, May 17, 2017 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on new immunotherapies, today announced that it will present updated results from...
May 12, 2017 09:20 ET | Source: ZIOPHARM Oncology, Inc.

ZIOPHARM Oncology Announces Pricing of $50 Million Follow-On Offering of Common Stock

BOSTON, May 12, 2017 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on new immunotherapies, today announced that it has priced an underwritten...
May 02, 2017 07:00 ET | Source: ZIOPHARM Oncology, Inc.

ZIOPHARM Oncology Announces FDA Acceptance of IND for CD33-Specific CAR-T Cell Therapy Targeting Relapsed/Refractory Acute Myeloid Leukemia

BOSTON, May 02, 2017 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on new immunotherapies, today announced that an investigator-initiated...
May 01, 2017 16:05 ET | Source: ZIOPHARM Oncology, Inc.

ZIOPHARM Oncology Reports First Quarter 2017 Financial Results and Provides Update on Recent Activities

– Advancing Plans to Initiate Pivotal Study for Ad-RTS-hIL-12 + Veledimex for Treatment of Recurrent Brain Cancer – - Company to Host Conference Call Today at 4:30 p.m. ET - BOSTON, May 01,...
April 24, 2017 07:00 ET | Source: ZIOPHARM Oncology, Inc.

ZIOPHARM Oncology to Host First-Quarter 2017 Financial Results and Corporate Update Conference Call on May 1, 2017 at 4:30 p.m. ET

BOSTON, April 24, 2017 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on new immunotherapies, today announced that it will host a conference call and...
April 20, 2017 16:05 ET | Source: ZIOPHARM Oncology, Inc.

ZIOPHARM Oncology to Present Updated Clinical Results of Gene Therapy Candidate Ad-RTS-hIL-12 + Veledimex in Recurrent Glioblastoma at the 2017 ASCO Annual Meeting

BOSTON, April 20, 2017 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on new immunotherapies, today announced that it will present updated results...
April 03, 2017 07:00 ET | Source: ZIOPHARM Oncology, Inc.; Intrexon Corporation

Intrexon, ZIOPHARM and Merck KGaA, Darmstadt, Germany Advancing Next-Generation Non-Viral CAR-T Platform Empowered by Membrane-Bound IL-15 Under RheoSwitch Therapeutic System® Control

GERMANTOWN, Md. and BOSTON, April 03, 2017 (GLOBE NEWSWIRE) -- Intrexon Corporation (NYSE:XON), a leader in the engineering and industrialization of biology to improve the quality of life and health...
March 27, 2017 08:00 ET | Source: ZIOPHARM Oncology, Inc.

ZIOPHARM Announces Successful End-of-Phase 2 Meeting with FDA for Ad-RTS-hIL-12 Gene Therapy in Recurrent Glioblastoma

BOSTON, March 27, 2017 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on new immunotherapies, today announced the receipt of positive guidance from an...
March 27, 2017 07:00 ET | Source: ZIOPHARM Oncology, Inc.

ZIOPHARM Appoints Amy Trevvett Vice President of Investor Relations and Corporate Communications

BOSTON, March 27, 2017 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on new immunotherapies, today announced the appointment of Amy Trevvett as Vice...
February 16, 2017 16:05 ET | Source: ZIOPHARM Oncology, Inc.

ZIOPHARM Reports Fourth-Quarter 2016 Financial Results and Provides Update on Recent Activities

- Company to Webcast Corporate Update Thursday, February 23, at the 2017 RBC Global Healthcare Conference - BOSTON, Feb. 16, 2017 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a...